Aquestive Therapeutics, Inc. (AQST)
| Market Cap | 550.73M |
| Revenue (ttm) | 50.27M |
| Net Income (ttm) | -68.91M |
| Shares Out | 125.45M |
| EPS (ttm) | -0.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,384,613 |
| Open | 4.460 |
| Previous Close | 4.465 |
| Day's Range | 4.220 - 4.475 |
| 52-Week Range | 2.930 - 7.550 |
| Beta | 1.45 |
| Analysts | Strong Buy |
| Price Target | 8.89 (+102.51%) |
| Earnings Date | Aug 10, 2026 |
About AQST
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form ... [Read more]
Financial Performance
In 2025, Aquestive Therapeutics's revenue was $44.55 million, a decrease of -22.61% compared to the previous year's $57.56 million. Losses were -$83.78 million, 89.8% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for AQST stock is "Strong Buy." The 12-month stock price target is $8.89, which is an increase of 102.51% from the latest price.
News
Aquestive Therapeutics files to sell 230,271 shares of common stock for holders
16:21 EDT Aquestive Therapeutics (AQST) files to sell 230,271 shares of common stock for holders
Aquestive Therapeutics Registration statement: Registration filing
Aquestive Therapeutics filed a registration statement on June 26, 2026, providing details about a securities offering with the SEC.
Aquestive Therapeutics Transcript: AGM 2026
The meeting highlighted progress toward FDA approval and commercial launch of Anaphylm, global regulatory advances, and pipeline development. All shareholder proposals passed with strong support, and no material non-public information was disclosed during the Q&A.
Aquestive Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth, narrowed losses, and major regulatory progress for Anaphylm, with a robust cash position and new financing supporting launch readiness. International filings are on track, and early AQST-108 data show promise in dermatology.
Aquestive Therapeutics Earnings release: Q1 2026
Aquestive Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Aquestive Therapeutics Quarterly report: Q1 2026
Aquestive Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Aquestive Therapeutics Slides: Q1 2026
Aquestive Therapeutics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Aquestive Therapeutics reports Q1 EPS (7c), consensus (13c)
Reports Q1 revenue $14.45M, consensus $10.9M. “We made rapid and meaningful progress in the first quarter,” said Daniel Barber, President and Chief Executive Officer of Aquestive. “We successfully com...
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement ...
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement ...
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement ...
Aquestive Therapeutics Proxy statement: Proxy filing
Aquestive Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Aquestive Therapeutics Proxy statement: Proxy filing
Aquestive Therapeutics filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Aquestive Therapeutics assumed with an Outperform at Oppenheimer
Oppenheimer analyst Mazahir Alimohamed assumed coverage of Aquestive Therapeutics (AQST) with an Outperform rating and $8 price target The firm views Aquestive as a regulatory execution story for Anap...
AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt
Disclosure Under Scrutiny: Were Risk Warnings Adequate for Aquestive's Anaphylm NDA? NEW YORK, April 16, 2026 /PRNewswire/ -- SueWallSt examines the adequacy of Aquestive Therapeutics, Inc.'s (NASDAQ:...
Investor Sue Aquestive Therapeutics Over ‘Postage Stamp’ Anaphylaxis Treatment Claims
A class action lawsuit was filed against Aquestive Therapeutics ($AQST) on March 5, 2026. The federal securities class action alleges that plaintiffs acquired Aquestive stock at artificially inflated ...
AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST)? Did you purchase your shares between June 16, 2025 a...
Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA
Aquestive Therapeutics (AQST) announced the receipt of preliminary comments and successful completion of an in-person Type A meeting with the FDA regarding the resubmission of the company’s new drug a...
Aquestive chief legal officer, chief compliance officer Lori Braender steps down
Aquestive Therapeutics (AQST) announced the appointment of Thomas Zalewski as chief legal officer and chief compliance officer, effective April 2, succeeding Lori Braender, who will be stepping down a...
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A.
WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvemen...
AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt
Wall Street Reassessment: Analyst Opinion Evolution on AQST NEW YORK, March 12, 2026 /PRNewswire/ -- On January 9, 2026, Cantor slashed its price target on Aquestive Therapeutics, Inc. (NASDAQ: AQST) ...
Aquestive Therapeutics Transcript: The Citizens Life Sciences Conference 2026
FDA requested additional human factors and PK studies for Anaphylm, with resubmission planned for Q3. Market demand for needle-free epinephrine remains strong, and launch preparations are supported by robust cash reserves and expanded medical affairs efforts.
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvemen...
Aquestive Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Anaphylm remains the central focus, with remediation efforts on track for Q3 2024 resubmission and potential early 2025 approval. The company is well-capitalized, expanding its sales force, and expects strong adoption among younger patients, with broader pipeline and market opportunities ahead.
AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acqui...